Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Stoffenmanager Nano version 1.0: a web-based tool for risk prioritization of airborne manufactured nano objects.

Van Duuren-Stuurman B, Vink SR, Verbist KJ, Heussen HG, Brouwer DH, Kroese DE, Van Niftrik MF, Tielemans E, Fransman W.

Ann Occup Hyg. 2012 Jul;56(5):525-41. doi: 10.1093/annhyg/mer113. Epub 2012 Jan 20.

PMID:
22267129
2.

Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.

van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA.

FASEB J. 2011 Jan;25(1):280-9. doi: 10.1096/fj.10-163709. Epub 2010 Sep 27.

PMID:
20876209
3.

Use of read-across and tiered exposure assessment in risk assessment under REACH--a case study on a phase-in substance.

Vink SR, Mikkers J, Bouwman T, Marquart H, Kroese ED.

Regul Toxicol Pharmacol. 2010 Oct;58(1):64-71. doi: 10.1016/j.yrtph.2010.04.004. Epub 2010 Apr 13.

PMID:
20394791
4.

Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.

Zerp SF, Vink SR, Ruiter GA, Koolwijk P, Peters E, van der Luit AH, de Jong D, Budde M, Bartelink H, van Blitterswijk WJ, Verheij M.

Anticancer Drugs. 2008 Jan;19(1):65-75.

PMID:
18043131
5.

Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.

Vink SR, van der Luit AH, Klarenbeek JB, Verheij M, van Blitterswijk WJ.

Biochem Pharmacol. 2007 Nov 15;74(10):1456-65. Epub 2007 Aug 3.

PMID:
17803969
6.

A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells.

van der Luit AH, Vink SR, Klarenbeek JB, Perrissoud D, Solary E, Verheij M, van Blitterswijk WJ.

Mol Cancer Ther. 2007 Aug;6(8):2337-45.

7.

Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.

Vink SR, van Blitterswijk WJ, Schellens JH, Verheij M.

Cancer Treat Rev. 2007 Apr;33(2):191-202. Epub 2007 Feb 6. Review.

PMID:
17287087
8.

TRAIL enhances efficacy of radiotherapy in a p53 mutant, Bcl-2 overexpressing lymphoid malignancy.

Wissink EH, Verbrugge I, Vink SR, Schader MB, Schaefer U, Walczak H, Borst J, Verheij M.

Radiother Oncol. 2006 Aug;80(2):214-22. Epub 2006 Aug 17.

PMID:
16916556
9.

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.

Vink SR, Schellens JH, Beijnen JH, Sindermann H, Engel J, Dubbelman R, Moppi G, Hillebrand MJ, Bartelink H, Verheij M.

Radiother Oncol. 2006 Aug;80(2):207-13. Epub 2006 Aug 17.

PMID:
16914220
10.

Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.

Vink SR, Lagerwerf S, Mesman E, Schellens JH, Begg AC, van Blitterswijk WJ, Verheij M.

Clin Cancer Res. 2006 Mar 1;12(5):1615-22.

11.

Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.

Veldman RJ, Koning GA, van Hell A, Zerp S, Vink SR, Storm G, Verheij M, van Blitterswijk WJ.

J Pharmacol Exp Ther. 2005 Nov;315(2):704-10. Epub 2005 Jul 22.

PMID:
16040815
12.

Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Vink SR, Schellens JH, van Blitterswijk WJ, Verheij M.

Invest New Drugs. 2005 Aug;23(4):279-86.

PMID:
16012787

Supplemental Content

Support Center